Skip to main content
Equibles
LFST logo

LFST · LifeStance Health Group, Inc.

Track LFST — free

Use LFST with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$12.73 -0.10 (-0.78%) At close · Sep 4
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$4.95B
Shares
382.06M

LFST metrics

78 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$12.73
Market cap
$4.95B

Price action

19 metrics
Price change (1W)
+4.3%
Price change (30D)
+20.4%
Price change (3M)
+67.9%
Price change (6M)
+84.6%
Price change (YTD)
+82.2%
Price change (1Y)
+133.7%
Trailing year
Price change (5Y)
-21.0%
52-week high
$12.89
52-week low
$4.81
Change from 52-week high
-0.5%
Change from 52-week low
+166.7%
Annualized volatility
53.6%
Beta
0.7
RSI (14D)
65.6
Price vs SMA 50
+12.4%
Price vs SMA 200
+56.4%
Avg volume (3M)
3.82M
Relative volume
1.1
Average dollar volume
$41.62M

Company

3 metrics
Sector
Healthcare
Industry
Medical Care Facilities
Shares outstanding
382.06M

Valuation

12 metrics
P / E (TTM)
97.8
Trailing earnings · reciprocal yield 1.0%
PEG ratio
—
EV / revenue
3.2×
reciprocal yield 31.7%
EV / EBITDA
41.4×
reciprocal yield 2.4%
EV / EBIT
63.7×
reciprocal yield 1.6%
P / sales
3.1×
reciprocal yield 32.0%
P / book
3.3
reciprocal yield 29.9%
FCF yield
3.5%
TTM · current market cap
Buyback yield
—
P / FCF
28.5
reciprocal yield 3.5%
P / operating cash flow
22.7
reciprocal yield 4.4%
Earnings yield
1.0%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
2.4×
reciprocal yield 42.1%
EV / revenue historical average (5Y)
2.6×
reciprocal yield 38.6%
EV / EBIT historical average (3Y)
151.2×
reciprocal yield 0.7%
EV / EBIT historical average (5Y)
151.2×
reciprocal yield 0.7%
EV / EBITDA historical average (3Y)
90.9×
reciprocal yield 1.1%
EV / EBITDA historical average (5Y)
90.9×
reciprocal yield 1.1%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
—
Operating margin
4.9%
Trailing 12 months
Net margin
3.2%
Gross profit (TTM)
—
Operating profit (TTM)
$78.43M
Net income (TTM)
$50.60M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
11.0%
Effective tax rate
24.5%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
—

Growth

11 metrics
Revenue growth YoY
+26.1%
Year over year
Net income growth YoY
—
Revenue (TTM)
$1.58B
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+0.1%
Year over year · more shares
Revenue CAGR (3Y)
+18.3%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
3.4%
Return on assets
2.3%
Debt / equity
0.2
Current ratio
1.4
EBITDA (TTM)
$120.80M
Free cash flow (TTM)
$173.91M
Quick ratio
1.4
Interest coverage
7.8
Net debt / EBITDA
0.4
Return on invested capital
3.9%
Trailing 12 months
Net cash
−$47.55M
Latest balance sheet
Cash & equivalents
$225.94M
Total assets
$2.18B
Total debt
$273.49M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$217.87M
Capital expenditures (TTM)
$43.96M
R&D (TTM)
—
SG&A (TTM)
$398.86M
Stock compensation (TTM)
$69.95M
R&D / revenue
—
Stock compensation / revenue
4.4%

Ownership (13F)

3 metrics
13F filers
292
13F filer change QoQ
+63
Institutional ownership
98.5%

Short interest

3 metrics
Short interest
3.0%
Latest settlement · 2.0 days to cover
Days to cover
2.0d
Short-squeeze score
63 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$161.59M
Insider-sentiment score
5 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1845257 CUSIP 53228F101 13F (30d) 209 filings 209 filers Visit website Investor relations